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Abstract 
The functionalisation of therapeutic nanoparticle constructs with cancer-specific biomolecules 
can enable selective tumour accumulation and targeted treatment. Water soluble gold 
nanoparticles (ca. 4 nm) stabilised by a mixed monolayer of a hydrophobic zinc phthalocyanine 
photosensitiser (C11Pc) and hydrophilic polyethylene glycol (PEG) have been prepared. The 
C11Pc-PEG gold nanoparticle constructs were further functionalised with jacalin, a lectin specific 
for the cancer-associated Thomsen-Friedenreich (T) carbohydrate antigen, or with monoclonal 
antibodies specific for the human epidermal growth factor receptor-2 (HER-2). The two 
biofunctionalised nanoparticle conjugates produced similar levels of singlet oxygen upon 
irradiation at 633 nm. Importantly, both nanoparticle conjugates demonstrated extensive, yet 
comparable, phototoxicity in HT-29 colorectal adenocarcinoma cells (80-90%) and in SK-BR-3 
breast adenocarcinoma cells (>99%). Non-conjugated C11Pc-PEG gold nanoparticles were only 
minimally phototoxic. Lysosomal colocalisation studies performed with the HT-29 colon cancer 
cells and the SK-BR-3 breast cancer cells revealed that both nanoparticle conjugates were 
partially localised within acidic organelles, which is typical of receptor-mediated endocytosis. The 
similarity of the targeted PDT efficacy of the two biofunctionalised C11Pc-PEG gold nanoparticles 
is discussed with respect to targeting ligand binding affinity and cell surface antigen density as 
key determinants of targeting efficiency. This study highlights how targeting small cell-surface 
molecules, such as the T antigen, can mediate a selective photodynamic treatment response 
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which is similar to that achieved when targeting overexpressed protein receptors, such as HER-
2. The high prevalence of the T antigen present on the cellular surface of primary tumours 
emphasises the broad potential applications for lectin-targeted therapies.  
 
Introduction 
Photodynamic therapy (PDT) is based on the photochemical reaction between light and 
photosensitisers to generate therapeutic doses of cytotoxic singlet oxygen to efficiently treat 
cancers.1 Recently, a broad range of studies have reported the improved therapeutic efficacy and 
enhanced pharmacokinetic behaviour of some photosensitising agents when coupled to 
nanoparticles.2 Furthermore, nanoparticle systems can provide a robust platform for the 
conjugation of targeting agents in order to maximise the tumour selectivity of the 
photosensitiser-nanoparticle conjugate, while minimising any possible damage to healthy 
tissue.2 Targeted nanoparticle platforms exhibit an additional advantage over conventional 
bioconjugates in that they display multivalent effects and enhanced tumour avidity through the 
existence of multiple targeting ligands at the surface of an individual nanoparticle entity.3 
Active targeting of cancerous tissue relies on the identification of exogenous ligands with 
inherent or acquired selectivities and high binding affinities towards tumour-associated 
molecular targets. Overexpressed or newly expressed cell surface receptors that are not usually 
expressed in healthy cells are typical targets for selectively delivering cancer therapeutics to 
tumours. One of the most common methods of actively targeting tumour tissue is through the 
use of antibodies, antibody fragments or antibody mimetics, with an intrinsic therapeutic anti-
tumour potential.4 Antibodies are particularly attractive for targeted cancer treatment due to 
their high binding affinities with equilibrium dissociation constants (Kd) typically in the nanomolar 
range and also due to the broad range of pontential antigens. Antibody conjugates, so-called 
immunoconjugates, have seen wide-spread use for in vitro, in vivo and clinical cancer treatment.4 
Within PDT, a number of studies have reported the direct conjugation of a photosensitiser with 
a cancer-targeting antibody to generate photoimmunoconjugates for selective PDT treatment.5 
Levy et al. were the first to demonstrate the efficacy of using photoimmunoconjugates for 
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targeted PDT.6 This approach has since been adapted for a variety of antibodies, photosensitisers 
and bioconjugation techniques.5 Recently, tumour-activatable photoimmunoconjugates 
composed of an anti-epidermal growth factor receptor (EGFR) antibody and a self-quenching 
photosensitiser benzoporphyrin derivative have been used to target in vivo OVCAR-5 human 
ovarian carcinomas overexpressing EGFR.7 Multimodal treatment using this 
photoimmunoconjugate demonstrated a potent synergistic therapeutic effect through the down-
regulation of EGFR receptor signalling in addition to selective photodynamic destruction of 
tumour tissue.  
Human epidermal growth factor receptor-2 (HER-2) is of the EGFR tyrosine kinase family of 
transmembrane receptors which modulates a number of processes including apoptosis, 
migration, proliferation, growth, adhesion and proliferation.8 The HER-2 receptor is 
overexpressed in 10-34% of human breast cancers, and overexpression is correlated with poor 
disease prognosis.9 HER-2 overexpression directly increases cancer cell proliferation and 
migration, and also results in resistance to therapy and apoptotic induction.8 The HER-2 receptor 
is targeted in the clinic using the therapeutic monoclonal antibody trastuzumab (Herceptin), in 
particular for the treatment of HER-2 positive breast cancers.10 We have previously targeted 
human breast cancer cells that over-express the HER-2 receptor using zinc phthalocyanine-
polyethylene glycol (C11Pc-PEG) stabilised gold nanoparticles conjugated to monoclonal anti-
HER-2 antibodies.11 Following irradiation, the antibody functionalised nanoparticles selectively 
reduced the viability of HER-2 overexpressing cells. MDA-MB-231 breast cancer cells not 
expressing the HER-2 receptor and subnormal, non-transformed MCF-10A breast epithelial cells 
were largely unaffected by the HER-2 targeted PDT treatment.11 
An alternative cell surface target is the folate receptor. This receptor is overexpressed in more 
than 90% of human ovarian carcinoma cells and has therefore been extensively targeted with 
folate-chemotherapeutic conjugates to selectively deliver anti-cancer agents to tumour cells.12 
One of the earliest reported studies showed the effective folate targeting of KB human 
nasopharyngeal cancer cells using a folate-conjugated liposomal preparation of chloro-
aluminium phthalocyanine.13 More recently, folate modified porphysome structures have been 
described, that upon binding to tumour cell folate receptors, destabilise and become activated 
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thus enabling their photosensitising potential.14 Likewise, transferrin bioconjugates have been 
widely used for monitoring disease progression and for the targeted destruction of cancer cells 
overexpressing the transferrin receptor.15 The first example of transferrin targeted PDT was 
reported by Hamblin and Newman who demonstrated that a transferrin-haematoporphyrin 
conjugate exhibited a superior PDT efficacy in HT-29 colon cancer and NIH:3T3 cells, as compared 
to an albumin-haematoporphyrin conjugate.16 A number of oligopeptides with specific affinities 
towards cancer-associated targets have been identified as powerful cancer-targeting 
biomolecules. These include peptides containing the arginine-glycine-aspartate (RGD) sequence 
which target αvβ3 and αvβ5 integrins that are overexpressed by a number of cancer cells and 
activated angiogenic vascular endothelial cells.17 The first evidence of the targeted PDT efficacy 
using RGD conjugates described the enhanced phototoxicity of RGD-containing adenoviral 
proteins conjugated to sulfonated aluminium phthalocyanines in integrin-expressing A549 lung 
and HeP2 laryngeal cancer cells.18 
Carbohydrates have also been used to directly target endogenous lectins (carbohydrate binding 
proteins) with expression patterns that correlate with neoplastic transformation. The first report 
of carbohydrate targeting for PDT described the conjugation, characterisation and in vitro 
assessment of the photosensitiser chlorin e6 conjugated to a galactosyl polymer.19 More 
recently, mannose functionalised silica nanoparticles containing a porphyrin derivative 
photosensitiser have been used to target the specific lectin receptors overexpressed by HCT-116 
human colorectal adenocarcinoma cells.20 Targeting with mannose moieties doubled the PDT 
cytotoxicity of the silica nanoparticles in vitro and allowed for effective HCT-116 tumour 
reduction following in vivo PDT of a subcutaneous mouse model. Conversely, exogenous lectins, 
such as wheat germ agglutinin21 and peanut agglutinin22 have also been used for the targeting of 
cell surface carbohydrates that exhibit expression patterns that are associated with malignancy.  
The Thomsen-Friedenreich carbohydrate antigen (T antigen) is a truncated O-linked oncofoetal 
glycan that is exposed in more than 90% of primary tumours.23 The first report of using lectins 
for targeted photodynamic cancer therapy described the synthesis and PDT efficacy of a 
conjugate composed of the lectin, Morniga G, and a water soluble porphyrin photosensitiser.24 
PDT using the Morniga G-porphyrin conjugate, targeted towards the T antigen, reduced Jurkat 
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leukaemia cell viability by more than 90%, whereas the non-conjugated sensitiser had no 
phototoxic effects at the same concentration.24 We have previously shown that jacalin, a lectin 
specific for the T antigen, can selectively deliver C11Pc-PEG gold nanoparticles to HT-29 human 
colon adenocarcinoma cells that overexpress the T antigen. Targeted PDT treatment lead to an 
exceptional reduction in viability whereas incubation in the dark and non-targeted PDT treatment 
was largely non-cytotoxic.25  
In this present study, we compare, for the first time, the targeted PDT efficacy of C11Pc-PEG gold 
nanoparticles functionalised with either the lectin jacalin or with anti-HER-2 monoclonal 
antibodies. We demonstrate how targeting using lectins or antibodies can enhance PDT 
treatment response in both HT-29 colon cancer cells and in SK-BR-3 breast cancer cells, as 
compared to treatment with non-conjugated nanoparticles. We have shown that targeted PDT 
with jacalin or anti-HER-2 antibodies conjugated to our C11Pc-PEG nanoparticles induce similar 
levels of cytotoxicity. Our findings emphasise the importance of receptor density on cell surfaces 
in addition to the binding affinity of ligands for their respective targets when assessing potential 
targeting efficiency. With a high density of cancer-associated receptors on the cellular surface, 
the therapeutic value of weaker-binding targeting ligands may be significantly elevated. Finally, 
using confocal microscopy and lysosomal colocalisation studies, the internalisation mechanisms 
of the lectin or antibody nanoparticle conjugates in both cell lines have been analysed and found 
to be largely through the endocytic pathway. 
 
Materials and Methods 
Synthesis of the C11Pc-PEG gold nanoparticles and conjugation of targeting ligands 
The synthesis and purification of the C11Pc-PEG gold nanoparticles was performed as previously 
reported.25 Jacalin (Vector Laboratories) and monoclonal rat IgG2a anti-HER-2 antibodies 
(Abcam) were covalently conjugated to the PEG carboxyl groups on the C11Pc-PEG gold 
nanoparticles using N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide (EDC; Sigma-Aldrich) and 
N-hydroxysuccinimide (NHS; Fisher Scientific). The carboxyl moieties on the PEG were converted 
to amine-reactive NHS esters by stirring the C11Pc-PEG gold nanoparticles (2 ml, 6 μM C11Pc 
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equivalent) for 30 min at room temperature in 50 mM MES buffer (pH 5.5, 0.05% Tween 20) with 
2 mM EDC (0.8 μl, 0.877 g/ml) and 5 mM NHS (1.2 mg, 115.08 g/mol). Unreacted EDC and NHS 
were removed by ultrafiltration of the NHS-ester functionalised C11Pc-PEG gold nanoparticles in 
four separate 500 μl aliquots in VivaspinTM 500 tubes (100 kDa molecular weight cut off (MWCO), 
polyethersulfone (PES); Sartorius Stedim Biotech). The ultrafiltration procedure was performed 
by centrifuging the nanoparticle samples in the VivaspinTM 500 tubes at 14,300 xg for 30 min at 
4°C. The NHS-ester functionalised C11Pc-PEG gold nanoparticles in two of the VivaspinTM 500 
tubes were each redispersed in 10 mM HEPES buffered saline (500 μl; pH 7.4, 150 mM NaCl, 100 
μM CaCl2). The nanoparticle samples in the two remaining VivaspinTM 500 tubes were each 
redispersed in 10 mM phosphate buffered saline (PBS, 500 µl; pH 7.4, 150 mM NaCl, 100 μM 
CaCl2.2H2O). Jacalin (15.87 µl, 1 mg.ml-1) was added to the NHS-ester functionalised C11Pc-PEG 
gold nanoparticles dispersed in the HEPES buffered saline (1 ml) and anti-HER-2 antibodies (18.51 
µl, 1 mg.ml-1) were added to the nanoparticles dispersed in the PBS (1 ml). The HEPES and PBS 
buffers are recommended by the suppliers of jacalin and the antibody, respectively. The final 
concentration of jacalin or anti-HER-2 antibodies mixed with the nanoparticles was 0.24 µM. The 
jacalin and the anti-HER-2 antibodies were stirred with the NHS-ester functionalised C11Pc-PEG 
gold nanoparticles overnight at room temperature. Unbound jacalin and anti-HER-2 antibodies 
were removed from the conjugated nanoparticles by six repeated ultrafiltrations of the 
nanoparticle samples in 500 μl aliquots in VivaspinTM 500 tubes (100 kDa MWCO, PES) by 
centrifuging at 14,300 xg at 4°C for 30 min. After the sixth centrifugation the jacalin conjugated 
or anti-HER-2 antibody conjugated C11Pc-PEG nanoparticles prepared for use with the HT-29 
cells were redispersed in serum-free Roswell Park Memorial Institute (RPMI) 1640 medium 
(Invitrogen) supplemented with 1.5 mM L-glutamine (L-Gln; Invitrogen), as previously 
recommended in a study of jacalin and HT-29 cells.26 The jacalin or anti-HER-2 antibody 
conjugated C11Pc-PEG gold nanoparticles prepared for use with the SK-BR-3 cells were 
redispersed in serum-free Dulbecco’s Modified Eagle Medium (DMEM; Invitrogen) supplemented 
with 1 mM L-Gln, as previously described.11 As a control, non-conjugated C11Pc-PEG gold 
nanoparticles were also prepared in serum-free RPMI 1640 medium or serum-free DMEM 
medium, depending on the cell line used. All nanoparticle preparations were characterised using 
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a Hitachi U-3010 UV-visible absorption spectrophotometer, appropriately diluted for in vitro 
experiments using either serum-free RPMI 1640 medium or serum-free DMEM medium, and 
stored at 4°C. 
 
Singlet oxygen measurement of the jacalin conjugated or anti-HER-2 antibody conjugated 
C11Pc-PEG gold nanoparticles 
The production of singlet oxygen following the irradiation of jacalin conjugated or anti-HER-2 
antibody conjugated C11Pc-PEG gold nanoparticles was measured using the molecular probe 
anthracene-9,10-dipropionic acid disodium salt (ADPA, 366.32 g.mol-1; Molecular Probes).27 The 
singlet oxygen production of both conjugates was compared to that of non-conjugated C11Pc-
PEG. Non-conjugated, jacalin conjugated or anti-HER-2 antibody conjugated C11Pc-PEG gold 
nanoparticles were centrifuged in 500 µl aliquots in VivaspinTM 500 tubes at 14,300 xg for 30 min 
at 4°C. The nanoparticle samples were each redispersed in 10 mM PBS (500 µl; pH 7.4, 150 mM 
NaCl, 100 μM CaCl2.2H2O). The C11Pc-PEG gold nanoparticle preparations (450 µl) were 
individually placed in a 1.5 ml stoppered quartz cuvette with ADPA (50 µl, 1.7 mM in methanol) 
and a magnetic stirrer bar. The samples were irradiated at 633 nm for 30 min using a 10 mW 
Helium-Neon (HeNe) Laser (JDS Uniphase) with continuous magnetic stirring. The absorbance of 
the ADPA was monitored at 400 nm every 5 min. 
 
Culturing HT-29 human colon adenocarcinoma cells and SK-BR-3 human breast 
adenocarcinoma cells 
HT-29 human colon adenocarcinoma cells (LGC Standards) were cultured in NUNC NunclonTM Δ 
T75 sterile culture flasks in RPMI 1640 medium supplemented with 1.5 mM L-Gln and 10% Foetal 
Bovine Serum (FBS). SK-BR-3 human breast adenocarcinoma cells (LGC Standards) were cultured 
in T75 culture flasks using DMEM supplemented with 1 mM L-Gln and 10% FBS. All cells were 
incubated in a humidified incubator at 37°C in a 5% CO2 atmosphere and grown to ca. 75% 
confluency prior to use. 
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Comparative targeted PDT of HT-29 cells – MTT viability assay 
HT-29 cells at a ca. 75% confluency were trypsinised by washing once in PBS (5 ml) then once in 
0.25 % Trypsin with EDTA (1 ml; Invitrogen). The HT-29 cells were incubated at 37°C in a 5% CO2 
atmosphere for ca. 3 min until the cells detached from the culture flask. The detached cells were 
redispersed in RPMI 1640 medium supplemented with 1.5 mM L-Gln and 10% FBS (10 ml) and 
counted using a Neubauer hemocytometer. The HT-29 cells were seeded onto two separate 
white opaque NUNC NunclonTM ∆ Surface 96 well multidishes (100 µl, 2x104 cells per well; 
Thermo Fisher Scientific) 24 h prior to incubation with the nanoparticles. The medium was then 
aspirated and the cells were washed once in PBS (100 µl). The washed HT-29 cells were incubated 
with non-conjugated, jacalin conjugated or anti-HER-2 antibody conjugated C11Pc-PEG gold 
nanoparticles in serum-free RPMI 1640 medium (50 µl; 0.00, 0.10, 0.20, 0.50, 1.00 or 1.15 µM 
equivalent of C11Pc) for 3 h at 37°C in a 5% CO2 atmosphere. Following incubation, the cell 
medium containing nanoparticles was aspirated and the cells were washed 3 times in PBS (100 
µl). Finally the cells were kept in RPMI 1640 medium supplemented with 1.5 mM L-Gln and 10% 
FBS (200 µl). Staurosporine (20 µM; LC Labs) was used as a positive control for cytotoxicity.28 One 
of the 96 well multidishes was kept in the dark as a control. The cells in the remaining 96 well 
multidish were irradiated for 6 min per well using a 10 mW 633 nm HeNe laser fitted with a 
biconvex diverging lens, giving a fluency rate of 29 mW.cm-2 and a total light dose of 10.5 J.cm-2. 
Light intensity was measured using a Power Max 500AD Molectron power meter. The laser was 
positioned 50 cm above the cells. Following irradiation, the cells were incubated at 37 °C in a 5% 
CO2 atmosphere for 48 h. MTT reagent (10 µl, 5 mg.ml-1 in PBS) was added to each well and the 
cells were incubated at 37 °C in a 5% CO2 atmosphere for 4 h. The well contents were then 
removed and the formazan was dissolved in DMSO (200 µl). The well contents were transferred 
to transparent 96 well multidishes and the absorbance was measured at 550 nm using a MRX-
Dynatech plate reader. Background absorbance at 550 nm of RPMI 1640 medium alone 
incubated with MTT reagent was subtracted from all measurements. Cell viability was calculated 
as a percentage of absorbance at 550 nm of untreated, non-irradiated HT-29. All assays were 
performed in triplicate.  
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Comparative targeted PDT of SK-BR-3 cells – CellTiter-BlueTM viability assay 
SK-BR-3 cells at a ca. 75% confluency were trypsinised and seeded into 96 well multidishes for 24 
h as described for the HT-29 cells. The SK-BR-3 cells were washed once in PBS (100 µl) prior to 
incubation with the nanoparticles. The washed SK-BR-3 cells were incubated with non-
conjugated, jacalin conjugated or anti-HER-2 antibody conjugated C11Pc-PEG gold nanoparticles 
in serum-free DMEM medium (50 µl; 0.00, 0.10, 0.20, 0.50, 1.00 or 1.15 µM equivalent of C11Pc) 
for 3 h at 37°C in a 5% CO2 atmosphere. Following incubation, the cell medium containing 
nanoparticles was aspirated and the cells were washed 3 times in PBS (100 µl). Finally the cells 
were kept in DMEM medium supplemented with 1 mM L-Gln and 10% FBS (200 µl). Staurosporine 
(20 µM) was used as a positive control for cytotoxicity. One of the 96 well multidishes was kept 
in the dark as a control. The cells in the remaining 96 well multidish were irradiated for 6 min per 
well using the 633 nm HeNe. Following irradiation, the cells were incubated for 48 h at 37°C in a 
5% CO2 atmosphere. CellTiter-BlueTM reagent (20 µl per well) was added to the cells and 
incubated for 4 h at 37 °C in a 5% CO2 atmosphere. Fluorescence emission at 590 nm (excitation 
at 560 nm) was measured using an EnVisionTM (Wallac) 2103 Multilabel Reader (Perkin Elmer) 
equipped with an EnVisionTM work station. Background fluorescence emission at 590 nm of 
DMEM medium alone incubated with CellTiter-BlueTM reagent was subtracted from all 
measurements. Cell viability was calculated as a percentage of fluorescence emission at 590 nm 
of untreated, non-irradiated SK-BR-3 cells. All assays were performed in triplicate. 
 
Colocalisation studies using laser scanning confocal microscopy 
The HT-29 cells and the SK-BR-3 cells were seeded (2x104 cells per well) onto 18 mm round glass 
coverslips (Jencons VWR) in transparent 6 well multidishes (Thermo Fisher Scientific) for 48 h 
prior to nanoparticle incubation. The cells were then washed once in PBS (1 ml) and incubated 
for 3 h with serum-free RPMI 1640 medium (HT-29 cells) or serum-free DMEM medium (SK-BR-3 
cells) containing jacalin or anti-HER-2 antibody conjugated C11Pc-PEG gold nanoparticles (1 µM 
C11Pc equivalent, 1 ml). Following incubation with the nanoparticles, the cells were washed 3 
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times in PBS (1 ml) and finally kept in their respective media containing 10% FBS (2 ml). The cells 
were incubated for 15 h at 37 °C in a 5% CO2 atmosphere. Prior to imaging, the cells were 
incubated for 1 h with LysoSensorTM Green DND-189 (1 µM from 1 mM stock in DMSO; 
Invitrogen). The coverslips were mounted on a heated stage (37 °C) and 1 ml imaging medium 
(120 mM NaCl, 5 mM KCl, 2 mM CaCl2.2H2O, 1 mM MgCl2.4H2O, 1 mM NaH2PO4, 1 mM NaHCO3, 
25 mM HEPES, 11 mM glucose, and 1 mg.ml-1 BSA) was added to each coverslip. The cells were 
visualised with differential interference contrast (DIC) imaging using transmitted light from the 
458 nm line of an Argon ion laser. The fluorescence of the C11Pc-PEG gold nanoparticles was 
visualised using excitation from a 633 nm HeNe laser and the red emission was collected using a 
650 nm long pass filter. The fluorescence of the LysoSensorTM Green DND-189 was visualised 
using excitation from the 458 nm line of the Argon ion laser and the green emission was collected 
using a 475-525 nm band pass filter. Colocalisation of the C11Pc-PEG gold nanoparticles with the 
LysoSensorTM Green DND-189 was assessed by the yellow coloration of the merged red and green 
fluorescence images overlaid with the DIC images. 
 
Results 
Preparation of photoactive lectin and antibody nanoparticle conjugates 
Zinc phthalocyanine-polyethylene glycol (C11Pc-PEG) functionalised gold nanoparticles (ca. 4 
nm) were synthesised as previously reported.25 The synthetic procedure involved the reduction 
of gold chloride by sodium borohydride in the presence of both α-thio-ω-carboxy PEG and a 
thiolated 11-alkyl zinc phthalocyanine (C11Pc). The water soluble C11Pc-PEG gold nanoparticles 
(6 µM C11Pc equivalent) were covalently bound to jacalin or rat monoclonal anti-HER-2 IgG2a 
antibodies using EDC/NHS coupling. Based on the approximation that ca. 155 molecules of C11Pc 
were bound to each nanoparticle, a 6 μM solution of C11Pc-PEG gold nanoparticles contained ca. 
38.7 nM gold nanoparticles.25 By reacting a ca. 38.7 nM solution of EDC/NHS-activated C11Pc-
PEG gold nanoparticles with 240 nM jacalin or anti-HER-2 antibodies the targeting ligands were 
at a 6.2-fold molar excess of gold nanoparticles. Therefore, it is thought that approximately 6 
targeting ligands were present on each nanoparticle. Further, it was estimated that 65% of the 
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PEG molecules on each nanoparticle remain unconjugated. Figure 1 shows schematic 
representations of jacalin conjugated (A) and anti-HER-2 antibody conjugated (B) C11Pc-PEG gold 
nanoparticles. 
 
 
Figure 1 Schematic representations of C11Pc-PEG gold nanoparticles covalently bound to 
A) jacalin or B) anti-HER-2 antibodies. The gold nanoparticles are depicted as the 
core spherical clusters, the PEG molecules are shown as black linear polymer 
molecules, and the C11Pc photosensitiser is shown as blue, surface-bound 
macrocyclic structures. Images of jacalin (PDB ID 1M26)29 and the IgG2a antibody 
(PDB ID 1IGT)30 were generated using PyMOL. 
 
To compare the PDT efficiency of the jacalin conjugates with that of the anti-HER-2 antibody 
conjugates, the singlet oxygen production following the irradiation of the conjugated C11Pc-PEG 
gold nanoparticles was investigated. Non-conjugated C11Pc-PEG gold nanoparticles were used 
as a control. The production of singlet oxygen was measured in PBS using anthracene-9,10-
dipropionic acid disodium salt (ADPA) as the colorimetric singlet oxygen probe.27 ADPA exhibits 
characteristic absorption bands from 300-400 nm, which photobleach when the molecule reacts 
with singlet oxygen to produce an endoperoxide. The quantification of singlet oxygen was 
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calculated using a 1:1 molar stoichiometry of singlet oxygen to ADPA. The number of moles of 
singlet oxygen produced were normalised to the concentration of C11Pc equivalent present in 
the nanoparticle samples. Figure 2 shows that there is no significant difference in the quantity of 
singlet oxygen produced following the irradiation of the C11Pc-PEG gold nanoparticles 
conjugated to either jacalin (Figure 2, green) or the anti-HER-2 antibody (Figure 2, blue). 
Following conjugation to either targeting proteins, the singlet oxygen production of the 
nanoparticle conjugates appears to be marginally less than that produced by the non-conjugated 
C11Pc-PEG gold nanoparticles (Figure 2, black). However, the slight reduction in photoactivity 
following conjugation of the nanoparticles to either of the targeting ligands should be 
compensated by significantly enhanced cellular internalisation of the conjugates. Previously, we 
have shown that irradiation at 633 nm of ‘control’ (C11Pc-free) PEG gold nanoparticles (ca. 4 nm 
in diameter) in the presence of ADPA did not result in any photobleaching of ADPA, confirming 
that the C11Pc is essential for the production of singlet oxygen.11 
 
 
Figure 2 Singlet oxygen production following the irradiation at 633 nm of non-conjugated 
(black), jacalin conjugated (green) and anti-HER-2 antibody conjugated (blue) 
C11Pc-PEG gold nanoparticles. All nanoparticle samples were irradiated in 10 mM 
PBS (pH 7.4, 150 mM NaCl, 100 μM CaCl2.2H2O) in the presence of the colorimetric 
singlet oxygen molecular probe ADPA. 
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Targeted PDT efficacy of the conjugated nanoparticles 
We have reported previously the absorption, excitation and emission spectra of C11Pc assembled 
on gold nanoparticles.31,32 The absorption maximum of the phthalocyanine on the gold 
nanoparticles is ca. 690 nm. In this present study, with consideration of the convenience of using 
a Helium Neon laser, we excited the C11Pc-PEG gold nanoparticle conjugates within the cells at 
633 nm. This wavelength is within the phthalocyanine absorption band envelope, and has been 
shown previously to be a suitable wavelength for the irradiation of anti-HER2 antibody or jacalin 
conjugated C11Pc-PEG nanoparticles within cancer cell lines.11, 25 Additionally, to ensure that the 
lectin ligand targets the specific cell surface receptor, we have previously demonstrated that the 
targeted phototoxicity of the jacalin conjugated nanoparticles was competitively inhibited by the 
presence of the free sugar methyl-α-galactopyrannoside or the T antigen-expressing glycoprotein 
asialofetuin.25 Similarly, the selectivity of anti-HER-2 antibody was highlighted by showing that 
the antibody conjugated nanoparticles were not phototoxic to breast cancer cell lines (MDA-MB-
231 and MCF-10A) that do not over-express the HER-2 receptor.11   
HT-29 human colon adenocarcinoma cells were incubated with non-conjugated, jacalin 
conjugated or anti-HER-2 antibody conjugated C11Pc-PEG gold nanoparticles (0.00-1.15 μM 
C11Pc equivalent) and irradiated at 633 nm at a final light dose of 10.5 J.cm-2. Treatment response 
of the HT-29 cells was assessed using a MTT viability assay 48 h following PDT. The viability of the 
cells following jacalin targeted or anti-HER-2 antibody targeted PDT is shown in Figure 3 (A and 
B respectively). Following irradiation, viability of the HT-29 cells incubated with 1.15 μM C11Pc 
equivalent of the jacalin conjugated or anti-HER-2-conjugated nanoparticles was reduced to ca. 
10.1% and ca. 19.2%, respectively. Statistical significance was calculated using a one-tailed 
student’s t-test, which confirmed a statistically significant reduction in viability following 
irradiation (P<0.05). Without irradiation, at the same nanoparticle concentration, viability 
remained at ca. 62.0% and ca. 77.3%, respectively. No significant difference in the dose-
dependent phototoxicity of the HT-29 cells was observed following targeted PDT treatment using 
jacalin conjugated (Figure 3C, green) or anti-HER-2 antibody conjugated (Figure 3C, blue) 
nanoparticles at concentrations of 0.0-0.5 μM C11Pc equivalent.  
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At 1.15 μM C11Pc equivalent, phototoxicity induced by the jacalin conjugated nanoparticles was 
ca. 9.3% greater than that induced by the anti-HER-2 antibody conjugated particles (P<0.05). 
However, at the nanoparticle concentration of 1.15 μM C11Pc equivalent the jacalin conjugated 
particles exhibited a greater level of dark toxicity, ca. 38% reduction in viability, as compared to 
the dark toxicity of the antibody conjugates, ca. 23% reduction in viability. Partial reductions in 
the metabolic activities of cells incubated with the jacalin conjugated nanoparticles were 
observed without irradiation. Reduction in cellular metabolic activity is a common non-toxic 
biological response induced by jacalin binding that is dependent on lectin concentration, cell type 
and could be influenced by passage number.26 In HT-29 cells, jacalin has been found to interfere 
with the pro-survival mitogen-activated protein kinase (MAPK) signalling pathway.33 Analogous 
to HER-2 downregulation that is observed during HER-2 targeted therapies, the anti-proliferative 
biological effects of jacalin could be exploited to provoke a combined synergistic anti-tumour 
effect, further amplifying the effectiveness of jacalin targeted PDT. Irradiation of HT-29 cells 
incubated with 0.00-1.15 μM C11Pc equivalent of non-conjugated nanoparticles did not result in 
any significant phototoxicity, as the viability of HT-29 cells incubated with the highest 
nanoparticle concentration remained at 94% following irradiation (Figure 3C, black). At 
nanoparticle concentrations of 0.20-1.15 μM C11Pc equivalent, targeted PDT treatment using 
either jacalin or anti-HER-2 antibody conjugates potentiated significant phototoxicity of the HT-
29 cells, as compared to non-targeted treatment (P<0.05). Such enhancement emphasises the 
critical significance of using cancer-cell selective endocytic ligands such as lectins and antibodies 
to minimise non-specific photodamage. 
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Figure 3 MTT viability assay results of HT-29 cells following PDT treatment with: (A) the 
jacalin conjugated; or (B) anti-HER-2 antibody conjugated C11Pc-PEG gold 
nanoparticles. Cells were irradiated at 633 nm for 6 min per well (orange) or non-
irradiated (dark cyan). C) Phototoxicity of HT-29 cells incubated with the jacalin 
conjugated (green line), anti-HER-2 antibody conjugated (blue line) or non-
conjugated (black line) nanoparticles. Staurosporine (+St, 20 μM) was used as a 
positive control for cytotoxicity. Cells irradiated but not incubated with 
nanoparticles (+Irr) were also used as a control. (Error bars are ± 95% confidence 
intervals, n=3. * indicates statistical significance in viability reduction following 
irradiation at P<0.05 using a one-tailed t-test.) 
 
Targeted PDT using jacalin or anti-HER-2 antibody nanoparticle conjugates was also investigated 
with the SK-BR-3 human breast adenocarcinoma cells. A MTT assay was attempted with the SK-
BR-3 cells following targeted PDT treatment. However, residual DMEM medium in the wells 
during the formazan solubilisation step caused significant variation in the formazan colour (data 
not shown).34 Therefore, the CellTiter-BlueTM fluorimetric cell viability assay was performed with 
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the SK-BR-3 cells following targeted PDT treatment since no solubilisation step is involved with 
this assay.  
Figure 4 clearly demonstrates that following targeted PDT, with the same range of nanoparticle 
concentrations, the viability of the SK-BR-3 cells appears to be significantly lower than that of the 
HT-29 cells. The lower viability of the SK-BR-3 cells could be due to the SK-BR-3 cells being more 
susceptible to phototoxicity by having less effective repair mechanisms, that facilitate recovery 
from oxidative damage, than the HT-29 cells.35 
At nanoparticle concentrations of 1 μM and 1.15 μM C11Pc equivalent, targeted PDT using either 
the jacalin (Figure 4A) or anti-HER-2 antibody (Figure 4B) conjugates dramatically reduced SK-
BR-3 cell viability with ˃99% cell kill. Viability, without irradiation, remained at ca. 58.9-70.2% 
(Figure 4A) and ca. 85.5-98.5% (Figure 4B), respectively. The limited dark toxicity observed with 
the anti-HER-2 antibody conjugates offers an obvious advantage over using the jacalin 
nanoparticle conjugates. As observed with the HT-29 cells, the phototoxicity of the SK-BR-3 cells 
induced by non-conjugated C11Pc-PEG gold nanoparticles was negligible at all nanoparticle 
concentrations used for these experiments (Figure 4C). A dose-dependence in phototoxicity of 
the SK-BR-3 cells incubated with the jacalin or anti-HER-2 antibody conjugated particles was also 
observed. Jacalin conjugation appeared to provide a statistically significant improved PDT effect 
at 0.10 μM C11Pc equivalent, as compared to anti-HER-2 antibody conjugation (P<0.05). 
However, this apparent improvement in PDT efficacy when targeting SK-BR-3 cells using the 
jacalin conjugates (0.10 μM C11Pc equivalent) was accompanied by a ca. 4% greater dark toxicity 
than when the cells were incubated with the anti-HER-2 antibody conjugates. 
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Figure 4 CellTiter-BlueTM viability assay results of SK-BR-3 cells following PDT treatment 
with: (A) jacalin conjugated; or (B) anti-HER-2 antibody conjugated C11Pc-PEG 
gold nanoparticles. Cells were irradiated at 633 nm for 6 min per well (orange) or 
non-irradiated (dark cyan). C) Phototoxicity of SK-BR-3 cells incubated with the 
jacalin conjugated (green line), anti-HER-2 antibody conjugated (blue line) and 
non-conjugated (black line) nanoparticles. Staurosporine (+St, 20 μM) was used as 
a positive control for cytotoxicity. Cells irradiated but not incubated with 
nanoparticles (+Irr) were also used as a control. (Error bars are ± 95% confidence 
intervals, n=3. * indicates statistical significance in viability reduction following 
irradiation at P<0.05 using a one-tailed t-test.) 
 
The HER-2 receptor is overexpressed in SK-BR-3 human breast adenocarcinoma cells and in HT-
29 human colorectal adenocarcinoma cells.36, 37 SK-BR-3 cells are reported to express ca. 1-2x106 
HER-2 receptors per cell,38 and IgG anti-HER-2 monoclonal antibodies are known to bind to these 
cells with a Kd of 14-36 nM.39 HT-29 cells are reported to express ca. 4.4 ± 0.3x107 T antigens per 
cell, while jacalin binds to the T antigen with a Kd of 500 nM.26 The cell viability results shown in 
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Figure 3 and Figure 4 suggest that the lower binding affinity of jacalin (Kd of 500 nM) is 
compensated by the higher expression levels of the T antigen (4.4x107 antigens per cell) when 
compared to the higher binding affinity of the anti-HER-2 antibody (Kd of 14-36 nM) for targeting 
the lower density HER-2 receptor (2x106 receptors per cell). The higher level of expression of the 
T antigen in combination with the tetravalency of jacalin exemplifies the potential of lectins as 
multivalent targeting agents that can selectively deliver therapeutic nanoparticles to cancer cells. 
Either as an alternative to antibodies or in combination with antibodies, lectin targeting has a 
distinct role in cancer therapeutics by providing selectivity for an independent class of biological 
targets in addition to intrinsic anti-tumour biological activities that are non-overlapping with 
those exhibited by antibodies. 
Once the PDT efficacy of the jacalin conjugated and the anti-HER-2 antibody conjugated C11Pc-
PEG gold nanoparticles with both HT-29 cells and SK-BR-3 cells had been established, the 
intracellular fate of both nanoparticle conjugates was examined using laser scanning confocal 
microscopy. HT-29 cells and SK-BR-3 cells were incubated with jacalin or anti-HER-2 antibody 
conjugated C11Pc-PEG gold nanoparticles (1 µM C11Pc equivalent). The cells were also incubated 
with LysoSensorTM Green DND-189, a marker of acidic organelles. It has been shown previously 
that nanoparticles, such as functionalised gold nanoparticles, can be internalised into cells 
through a receptor mediated endocytic pathway which results in intracellular accumulation 
within the endosomal compartments.40,41 Maturation of endosomes leads to their eventual 
acidification through combination with lysosomes via the endocytic degradation pathway.42 
Alternatively, internalised nanoparticles in the endosomes may be redirected to the extracellular 
domain prior to endosomal maturation and acidification.43 Colocalisation of nanoparticle 
conjugates with acidic organelle markers would suggest that the conjugates are uptaken through 
an endocytic pathway rather than passive diffusion by which many lipophilic photosensitisers can 
enter cells.42, 44  
Acidic organelles within the HT-29 cells and SK-BR-3 cells were visualised using the green 
fluorescent marker LysoSensorTM Green DND-189 (1 µM) using excitation at 458 nm. The 
fluorescence of C11Pc upon excitation at 633 nm was exploited to visualise the conjugated 
C11Pc-PEG gold nanoparticles (1 µM C11Pc equivalent) within the intracellular environment. 
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Colocalisation of the nanoparticle conjugates with LysoSensorTM Green DND-189 was assessed 
using the BioImageXD software which correlates the red and green channels present in one voxel 
(volumetric pixel). Regions of colocalised red and green fluorescence from the conjugated C11Pc-
PEG gold nanoparticles and the acidic organelles, respectively, were isolated and false coloured 
yellow. Figure 5 shows the laser scanning confocal microscope images of SK-BR-3 cells incubated 
with the jacalin conjugated C11Pc-PEG gold nanoparticles (Figure 5A, red) and LysoSensorTM 
Green DND-189 (Figure 5B, green). For the image shown in Figure 5B the brightness of the green 
channel was reduced by 9% for clarity; however, colocalisation isolation and analysis using the 
BioImageXD software was performed on unaltered images. Figure 5C (yellow) highlights the 
regions of colocalisation where the jacalin conjugated nanoparticles are in the vicinity of the 
LysoSensorTM Green DND-189 indicating their presence within the acidified endosomal 
compartments. The DIC image of the SK-BR-3 cells merged with the fluorescence images of the 
jacalin conjugated C11Pc-PEG gold nanoparticles and the LysoSensorTM Green DND-189 is shown 
in Figure 5D. Similar patterns of colocalisation were observed in the SK-BR-3 cells incubated with 
anti-HER-2 antibody conjugated C11Pc-PEG gold nanoparticles (Figure S1 in Supporting 
Information) and in the HT-29 cells incubated with the jacalin conjugated (Figure S2) or anti-HER-
2 antibody conjugated (Figure S3) C11Pc-PEG gold nanoparticles. The colocalisation analysis 
suggests that both nanoparticle conjugates are internalised within the endolysosomes in both 
HT-29 cells and SK-BR-3 cells. Intracellular localisation of photosensitising agents has a 
considerable effect on the mechanisms of cell death, as the lysosomal presence of a 
photosensitiser can promote sub-apoptotic and necrotic mechanisms of cell death.45 These 
findings agree with our previous results which suggest that jacalin targeted PDT induced cell 
death of HT-29 cells via necrosis.25 The perinuculear presence of the jacalin conjugated or anti-
HER-2 antibody conjugated nanoparticles in HT-29 cells and SK-BR-3 cells suggests that targeted 
PDT using such nanoparticle conjugates is potentially advantageous since there is a lower risk of 
genotoxicity.46 
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Figure 5 Confocal microscopy images of SK-BR-3 cells incubated with the jacalin conjugated 
C11Pc-PEG gold nanoparticles (1 μM C11Pc equivalent). A) Excitation of the 
conjugated C11Pc-PEG gold nanoparticles at 633 nm results in red fluorescence 
emission. B) Acidic organelles are visualised by the green fluorescence emission of 
LysoSensorTM Green DND-189 upon excitation at 458 nm. C) Colocalisation of the 
conjugated C11Pc-PEG gold nanoparticles and the LysoSensorTM Green DND-189 
is shown in yellow. D) The DIC image and the fluorescence images of C11Pc and 
the LysoSensorTM Green DND-189 were merged. (Scale bars are 10 μm). 
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Conclusions 
Cancer cell targeting using the lectin jacalin as a carbohydrate-specific targeting protein was 
compared to anti-HER-2 antibodies which target the overexpressed HER-2 receptor. Both 
targeting ligands were covalently conjugated to C11Pc-PEG gold nanoparticles and were found 
to produce similar quantities of singlet oxygen upon irradiation at 633 nm. The MTT viability assay 
showed that the nanoparticles conjugated to either jacalin or anti-HER-2 antibodies drastically 
reduced HT-29 colon cancer cell viability, as compared to the non-conjugated particles. At a 
nanoparticle concentration of 1.15 µM C11Pc equivalent, HT-29 cell viability was reduced to ca. 
10% and 19% following jacalin or anti-HER-2 antibody targeted PDT treatment, respectively. 
However, at the same concentration, viability of the HT-29 cells incubated with non-conjugated 
particles remained at ca. 94%. The targeted PDT efficiency of jacalin and anti-HER-2 antibody 
conjugated C11Pc-PEG gold nanoparticles was also compared with SK-BR-3 breast cancer cells 
and analysed using the CellTiter-Blue viability assay. The SK-BR-3 cells appeared to be significantly 
more susceptible to PDT damage than the HT-29 cells following treatment using the same 
concentration of nanoparticles. At a nanoparticle concentration of 1.15 µM C11Pc equivalent, 
SK-BR-3 cell viability was reduced to ca. 3% and 5% following targeted PDT treatment with 
nanoparticles conjugated to jacalin or anti-HER-2 antibodies, respectively. However, at the same 
concentration, non-conjugated nanoparticles reduced SK-BR-3 cell viability by only ca. 5% 
following irradiation. A clear advantage of anti-HER-2 antibody targeting is the lower levels of 
dark toxicity observed following incubation with either the HT-29 cells or the SK-BR-3 cells, as 
compared to dark incubation with the jacalin conjugates.  
The intracellular localisation of the jacalin conjugated and anti-HER-2 antibody conjugated 
C11Pc-PEG gold nanoparticles was investigated in both HT-29 cells and SK-BR-3 cells using laser 
scanning confocal microscopy. Accumulation of the targeted nanoparticle conjugates within 
acidic organelles was assessed by the colocalisation of the red C11Pc fluorescence from the 
conjugated nanoparticles with the green fluorescence of the LysoSensorTM Green DND-189 
lysosomal marker. The degree of colocalisation was analysed using BioImageXD software. It was 
found that both the jacalin conjugated and anti-HER-2 antibody conjugated nanoparticles 
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partially colocalised with the LysoSensorTM Green DND-189 and remained in the acidic organelles 
within both the HT-29 cells and the SK-BR-3 cells. Colocalisation suggests that both types of 
nanoparticle conjugates were internalised through receptor mediated endocytosis. Further 
investigations into nanoparticle internalisation and recycling of HER-2 receptors and T antigen-
bearing glycoproteins could provide a valuable insight into the differences of cellular uptake of 
the targeted nanoparticle conjugates. Based on the dissociation constants of jacalin binding to 
HT-29 cells (500 ± 50 nM)26 and anti-HER-2 antibodies binding to SK-BR-3 cells (14-36 nM),39 it 
was expected that targeting with the antibody would be significantly more effective than the 
lectin. However, it is reported that there are a significantly greater number of T antigens on HT-
29 cells (ca. 4.4x107 T antigens per cell) 26 as compared to the number of HER-2 receptors on SK-
BR-3 cells (ca. 1-2x106 HER-2 receptors per cell).38 Since the PDT efficacy of the C11Pc PEG gold 
nanoparticle conjugated to either the jacalin lectin or anti-HER-2 antibody was comparable for 
either cell line, our results suggest a critical role for cell surface receptor density on the outcome 
of targeted PDT treatments for cancer. Investigations into the binding kinetics of the nanoparticle 
conjugates to the cells could help highlight the subtle differences between using the lectin or the 
antibody. The results described outline how lectins, such as jacalin, may have great potential for 
targeted cancer therapy by exploiting the high levels of cancer-associated carbohydrate antigen 
expression. Additionally, the dual targeting of two cancer-associated receptors that are 
biochemically different in nature may expand the applications of selective PDT through 
combining both targeting ligands onto one bi-specific nanoparticle.  
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